Finally, Pfizer Inc. (NYSE:PFE) is up 1.6% today in response to the U.S. Patent and Trade Office’s reissuance of a patent for a key ingredient in anti-inflammatory drug Celebrex. The award will maintain Celebrex’s patent exclusivity for another year, pushing its expiration back to 2015. That’s great news for Pfizer: While the company’s revenue has fallen recently due to the loss of patent exclusivity for blockbuster drug Lipitor, Celebrex is no slouch on the sales front. The longer Pfizer Inc. (NYSE:PFE) can keep this drug’s exclusivity, the more time it’ll have to beef up its blockbuster drugs of the future.
The article The Dow Hits a Record, but Challenges Loom originally appeared on Fool.com and is written by an Carroll.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Walt Disney (NYSE:DIS). The Motley Fool owns shares of Bank of America, JPMorgan Chase & Co., and Walt Disney.
Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.